Abstract
Purpose
[11C]Cimbi-36 was recently developed as an agonist radioligand for brain imaging of serotonin 2A receptors (5-HT2A) with positron emission tomography (PET). This may be used to quantify the high-affinity state of 5-HT2A receptors and may have the potential to quantify changes in cerebral 5-HT levels in vivo. We here investigated safety aspects related to clinical use of [11C]Cimbi-36, including radiation dosimetry and in vivo pharmacology.
Procedures
[11C]Cimbi-36 was injected in rats or pigs, and radiation dosimetry was examined by ex vivo dissection or with PET scanning, respectively. Based on animal data, the Organ Level INternal Dose Assessment software was used to estimate extrapolated human dosimetry for [11C]Cimbi-36. The 5-HT2A receptor agonist actions of [11C]Cimbi-36 in vivo pharmacological effects in mice elicited by increasing doses of Cimbi-36 were assessed with the head-twitch response (HTR).
Results
The effective dose as extrapolated from both rat and pig data was low, 7.67 and 4.88 μSv/MBq, respectively. In addition, the estimated absorbed radiation dose to human target organs did not exceed safety levels. Administration of 0.5 mg/kg Cimbi-36 leads to significant HTR compared to saline, whereas 0.05 mg/kg Cimbi-36 (doses much larger than those given in conjunction with a PET scan) did not elicit a significant HTR.
Conclusions
Administration of tracer doses of [11C]Cimbi-36 does not seem to be associated with unusual radiation burden or adverse clinical effects.
References
Gonzalez-Maeso J, Weisstaub NV, Zhou M et al (2007) Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron 53:439–452
Lopez-Gimenez JF, Villazon M, Brea J et al (2001) Multiple conformations of native and recombinant human 5-hydroxytryptamine(2a) receptors are labeled by agonists and discriminated by antagonists. Mol Pharmacol 60:690–699
Paterson LM, Tyacke RJ, Nutt DJ et al (2010) Measuring endogenous 5-HT release by emission tomography: promises and pitfalls. J Cereb Blood Flow Metab 30:1682–1706
Narendran R, Hwang DR, Slifstein M et al (2005) Measurement of the proportion of D2 receptors configured in state of high affinity for agonists in vivo: a positron emission tomography study using [11C]N-propyl-norapomorphine and [11C]raclopride in baboons. J Pharmacol Exp Ther 315:80–90
Narendran R, Mason NS, Laymon CM et al (2010) A comparative evaluation of the dopamine D(2/3) agonist radiotracer [11C](−)-N-propyl-norapomorphine and antagonist [11C]raclopride to measure amphetamine-induced dopamine release in the human striatum. J Pharmacol Exp Ther 333:533–539
Martinez D, Narendran R (2010) Imaging neurotransmitter release by drugs of abuse. Curr Top Behav Neurosci 3:219–245
Finnema SJ, Varrone A, Hwang TJ et al (2012) Confirmation of fenfluramine effect on 5-HT(1B) receptor binding of [(11)C]AZ10419369 using an equilibrium approach. J Cereb Blood Flow Metab 32:685–695
Pinborg LH, Feng L, Haahr ME et al (2012) No change in [(11) C]CUMI-101 binding to 5-HT(1A) receptors after intravenous citalopram in human. Synapse 66:880–884
Ridler K, Plisson C, Rabiner EA et al (2011) Characterization of in vivo pharmacological properties and sensitivity to endogenous serotonin of [11C] P943: a positron emission tomography study in Papio anubis. Synapse 65:1119–1127
Ettrup A, Palner M, Gillings N et al (2010) Radiosynthesis and evaluation of 11C-CIMBI-5 as a 5-HT2A receptor agonist radioligand for PET. J Nucl Med 51:1763–1770
Ettrup A, Hansen M, Santini MA et al (2011) Radiosynthesis and in vivo evaluation of a series of substituted (11)C-phenethylamines as 5-HT (2A) agonist PET tracers. Eur J Nucl Med Mol Imaging 38:681–693
Finnema S, Ettrup A, Stepanov V et al (2011) Pilot study on receptor binding and serotonin sensitivity of [11C]CIMBI-36 in monkey brain [abstract]. J Nucl Med 52(Suppl 1):495
Stabin MG, Sparks RB, Crowe E (2005) OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 46(6):1023–1027
Stabin MG (2008) Fundamentals of nuclear medicine dosimetry. Springer, New York
Wilson AA, Ginovart N, Hussey D et al (2002) In vitro and in vivo characterisation of [11C]-DASB: a probe for in vivo measurements of the serotonin transporter by positron emission tomography. Nucl Med Biol 29:509–515
ICRP (2008) International Commission on Radiological Protection (ICRP) publication 106. Radiation dose to patients from radiopharmaceuticals: addendum 3 to ICRP publication 53
van der Aart J, Hallett WA, Rabiner EA et al (2012) Radiation dose estimates for carbon-11-labelled PET tracers. Nucl Med Biol 39:305–314
Braden MR, Parrish JC, Naylor JC et al (2006) Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists. Mol Pharmacol 70:1956–1964
Shulgin A, Shulgin A (1991) PIHKAL, a chemical love story. Transform Press, Berkeley, pp 1–978
Acknowledgments
The technical assistance of Cecilia Ratner, Hanne Demant Hansen, Jahangeer Sakhi, Letty Klarskov, Mette Værum Olesen, Bente Dall, Lasse Kofoed Bech, and Agnete Dyssegaard is gratefully acknowledged. This study was financially supported by the Lundbeck Foundation, University of Copenhagen, Faculty of Health Sciences, the John and Birthe Meyer Foundation, the Aase and Ejner Danielsen Foundation, the Arvid Nilsson Foundation, and the EU 6th Framework program DiMI: (LSHB-CT-2005-512146).
Conflict of Interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ettrup, A., Holm, S., Hansen, M. et al. Preclinical Safety Assessment of the 5-HT2A Receptor Agonist PET Radioligand [11C]Cimbi-36. Mol Imaging Biol 15, 376–383 (2013). https://doi.org/10.1007/s11307-012-0609-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11307-012-0609-4